PT  - JOURNAL ARTICLE
AU  - Xia, Yongxiang
AU  - Tang, Weiwei
AU  - Qian, Xiaofeng
AU  - Li, Xiangcheng
AU  - Cheng, Feng
AU  - Wang, Ke
AU  - Zhang, Feng
AU  - Zhang, Chuanyong
AU  - Li, Donghua
AU  - Song, Jinhua
AU  - Zhang, Hui
AU  - Zhao, Jie
AU  - Yao, Aihua
AU  - Wu, Xiaofeng
AU  - Wu, Chen
AU  - Ji, Guwei
AU  - Liu, Xisheng
AU  - Zhu, Feipeng
AU  - Qin, Lang
AU  - Xiao, Xuan
AU  - Deng, Zhenhua
AU  - Kong, Xiangyi
AU  - Li, Si
AU  - Yu, Yangyang
AU  - Xi, Wenjing
AU  - Deng, Wanglong
AU  - Qi, Chuang
AU  - Liu, Hanyuan
AU  - Pu, Liyong
AU  - Wang, Ping
AU  - Wang, Xuehao
TI  - Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
AID  - 10.1136/jitc-2022-004656
DP  - 2022 Apr 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e004656
VI  - 10
IP  - 4
4099  - http://jitc.bmj.com/content/10/4/e004656.short
4100  - http://jitc.bmj.com/content/10/4/e004656.full
SO  - J Immunother Cancer2022 Apr 01; 10
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.